<br>通过单细胞和批量测序分析探讨YBX1在肝癌预后价值和免疫特征中的作用,The Journal of Gene Medicine

当前位置： X-MOL 学术 › J. Gene Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

通过单细胞和批量测序分析探讨YBX1在肝癌预后价值和免疫特征中的作用
The Journal of Gene Medicine ( IF 3.2 ) Pub Date : 2024-03-07 , DOI: 10.1002/jgm.3680
Qingqing Zhang _{1,

2} , Bingye Zhu ₃ , Hongyan Yang ₄ , Fei Li _{1,

2} , Ying Qu _{1,

2} , Lungen Lu _{1,

2} , Qidi Zhang _{1,

2}

Affiliation

背景Y-box结合蛋白1（YBX1）在多种肿瘤的进展中发挥多种作用。然而，YBX1 在肝细胞癌（LIHC）的预后价值和免疫调节中的作用仍不清楚。本研究旨在探讨YBX1对LIHC患者肿瘤免疫调节和生存预测的影响。方法利用在线数据库进行YBX1相关表达谱以及单细胞和批量测序分析。 YBX1 表达通过定量实时 PCR (qRT-PCR)、蛋白质印迹和免疫组织化学进行验证。进行单变量/多变量 Cox 回归分析以确定总生存期 (OS) 的独立预测因子。使用ESTIMATE（即使用表达数据估计恶性肿瘤组织中的STromal和免疫细胞）算法和肿瘤免疫功能障碍和排除（TIDE）分析来评估YBX1和LIHC免疫之间的关系。结果YBX1在LIHC组织中过度表达和细胞系。高 YBX1 表达与较差的 OS 显着相关。单变量/多变量 Cox 回归分析显示，YBX1 是 LIHC 的独立预后因素。基因集富集分析表明，YBX1 与 LIHC 相关的多个信号通路相关。此外，YBX1在多种免疫细胞中表达，并与免疫细胞、免疫检查点标志物和肿瘤免疫微环境显着相关。 TIDE分析表明，YBX1高表达的LIHC患者表现出较高的T细胞功能障碍评分和较高的排除评分，以及较差的免疫治疗反应。结论YBX1在LIHC中发挥重要的致癌作用，并与免疫防御系统密切相关。 YBX1 抑制可能作为 LIHC 的潜在治疗方法。

"点击查看英文标题和摘要"

Exploration of YBX1 role in the prognostic value and immune characteristics by single‐cell and bulk sequencing analysis for liver hepatocellular carcinoma

BackgroundY‐box binding protein 1 (YBX1) plays a variety of roles in progression of multiple tumors. However, the role of YBX1 in prognostic value and immune regulation for liver hepatocellular carcinoma (LIHC) remains unclear. The present study aimed to examine the effect of YBX1 on the regulation of tumor immunity and survival prediction in LIHC patients.MethodsYBX1‐related expression profiles and single‐cell and bulk sequencing analysis were performed using online databases. YBX1 expression was validated by a quantitative real‐time PCR (qRT‐PCR), western blotting and immunohistochemistry. Univariate/multivariate Cox regression analysis was performed to determine independent predictors of overall survival (OS). The ESTIMATE (i.e., Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) algorithm and Tumor Immune Dysfunction and Exclusion (TIDE) analysis were used to assess the relationships between YBX1 and LIHC immunity.ResultsYBX1 was over‐expressed in LIHC tissues and cell lines. High YBX1 expression was significantly associated with poor OS. Univariate/multivariate Cox regression analysis revealed that YBX1 was an independent prognostic factor for LIHC. Gene set enrichment analysis revealed that YBX1 was associated with multiple signaling pathways correlated to LIHC. Additionally, YBX1 was expressed in multiple immune cells and was significantly correlated with immune cells, immune checkpoint markers and tumor immune microenvironment. The TIDE analysis demonstrated that LIHC patients with high YBX1 expression showed a higher T‐cell dysfunction score and a higher exclusion score, as well as poorer immunotherapy response.ConclusionsYBX1 plays crucial oncogenic roles in LIHC and is closely associated with the immune defense system. YBX1 inhibition may serve as a potential treatment for LIHC.

更新日期：2024-03-07

点击分享查看原文

点击收藏

阅读更多本刊新发论文